Abstract
In colorectal tumorigenesis, loss of function of the mismatch repair genes is closely associated with genomic instability at the nucleotide level whereas p53 deficiency has been linked with gross chromosomal instability. We have addressed the contribution of these two forms of genetic instability to tumorigenesis using mice mutant for Msh2 and p53. As previously reported, deficiency of both genes leads to rapid lymphomagenesis Here we show that heterozygosity for p53 also markedly reduces survival on an Msh2 null background. We characterized the patterns of genomic instability in a small set of tumours and showed that, as predicted p53 deficiency predisposes to aneuploidy and Msh2 deficiency leads to microsatellite instability (MSI). However, heterozygosity for p53 in the absence of Msh2 resulted in increased MSI and not aneuploidy. This implied role for p53 in modulating MSI was confirmed using a large cohort of primary fibroblast clones. The differences observed were highly significant (P<0.01) in both the fibroblast clones (which all retained p53 functionality) and the tumours, a proportion of which retained p53 functionality. Our results therefore demonstrate a dose sensitive role for p53 in the maintenance of genomic integrity at the nucleotide level.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR . 1995 Curr. Biol. 5: 931–936
Bouffler SD, Kemp CJ, Balmain A, Cox R . 1995 Cancer Res. 55: 3883–3889
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, Wyllie AH . 1996 Oncogene 12: 2641–2649
Carder PJ, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, Bird CC . 1993 Oncogene 8: 1397–1401
Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y . 2000 EMBO J. 19: 4967–4975
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH . 1993 Nature 362: 849–852
Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH . 1994 Oncogene 9: 1767–1773
Clarke AR, Cummings MC, Harrison DJ . 1995 Oncogene 11: 1913–1920
Clarke AR, Howard LA, Harrison DJ, Winton DJ . 1997 Oncogene 14: 2015–2018
Cottu PH, Muzeau F, Estreicher A, Flejou J-F, Iggo R, Thomas G, Hamelin R . 1996 Oncogene 13: 2727–2730
Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R . 1997 Nature Genet 17: 114–118
Cranston A, Fishel R . 1999 Mamm. Genome 10: 1020–1022
Degtyareva N, Subramanian D, Griffith JD . 2001 J. Biol. Chem. 276: 8778–8784
de Wind N, Dekker M, Berns A, Radman M, te Riele H . 1995 Cell 82: 321–330
Duckett DR, Bronstein SM, Taya Y, Modrich P . 1999 Proc. Natl. Acad. Sci. USA 96: 12384–12388
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A . 1992 Nature 356: 215–221
Dudenhoffer C, Rohaly G, Will K, Deppert W, Wiesmuller L . 1998 Mol. Cell. Biol. 18: 5332–5342
Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JYJ . 1999 Nature 399: 806–809
Hartwell L . 1992 Cell 71: 543–546
Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA . 1993 Oncogene 8: 2457–2467
Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M . 1995 Cancer Res. 55: 3721–3725
Jimenez GS, Nister M, Stommel JM, Beeche M, Barcase ER, Zhang X-Q, O'Gorman S, Wahl G . 2000 Nature Gen. 26: 37–43
Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D . 1992 Semin. Cancer Biol. 4: 41–46
Kolodner RD . 1995 Trends Biochem. Sci. 20: 397–401
Lee S, Elenbaas B, Levine A, Griffith J . 1995 Cell 81: 1013–1020
Lengauer C, Kinzler KW, Vogelstein B . 1997 Nature 386: 623–627
Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopoulos N, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW . 1995 Nature Genet. 9: 48–55
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T . 1993 Nature 362: 847–849
Mummenbrauer T, Janus F, Muller B, Wiesmuller L, Deppert W, Grosse F . 1996 Cell 85: 1089–1099
Ozbun MA, Jerry J, Kittrell FS, Medina D, Butel JS . 1993 Cancer Res. 53: 1646–1652
Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE, Salter DM, Bird CC, Wyllie AH, Hooper ML . 1994 Oncogene 9: 603–609
Rafferty JA, Clarke AR, Sellapan D, Koref MS, Frayling IM, Margison GP . 1996 Oncogene 12: 693–697
Reichmann A, Martin P, Levin B . 1981 Int. J. Cancer 28: 431–440
Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A, Liu B, Thomason A, Griesser H, Gallinger S, Ballhausen WG, Fishel R, Mak TW . 1995 Nature Genet 11: 64–70
Reitmair AH, Redston M, Cai JC, Chuang TC, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B, Mak TW . 1996 Cancer Res. 56: 3842–3849
Sansom OJ, Clarke AR . 2000 Mut. Res. Fund. Mol. Mechan. Mutagen. 452: 149–162
Sansom OJ, Toft NJ, Winton DJ, Clarke AR . 2001 Oncogene 20: 3580–3584
Shoemaker AR, Haigis KM, Baker SM, Dudley S, Liskay RM, Dove WF . 2000 Oncogene 19: 2774–2779
Toft NJ, Arends MJ, Wyllie AH, Clarke AR . 1998 Nature Genet. 18: 17
Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, Riele HT, Arends MJ, Wyllie AH, Margison GP, Clarke AR . 1999 Proc. Natl. Acad. USA 96: 3911–3915
Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA . 1998 EMBO J. 17: 4657–4667
Vindelov LL, Christensen IJ, Nissen NI . 1983 Cytometry 3: 323–327
Vogelstein B, Kinzler KW . 1992 Cell 70: 523–526
Vogelstein B, Kinzler KW . 1993 Trends Genet. 9: 138–141
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM . 1992 Cell 70: 937–948
Acknowledgements
We thank John Verth and his staff for animal care, Jennifer Doig for technical assistance and Nathalie Sphyris for help with the p53 immunohistochemistry and EMSA. This work was supported by grants from the Cancer Research Campaign. NJ Toft is a Leckie-Mactier Research Fellow supported by the Faculty of Medicine, University of Edinburgh. AR Clarke is a Royal Society Research Fellow.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toft, N., Curtis, L., Sansom, O. et al. Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background. Oncogene 21, 6299–6306 (2002). https://doi.org/10.1038/sj.onc.1205727
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205727
Keywords
This article is cited by
-
Molecular pathological classification of colorectal cancer
Virchows Archiv (2016)
-
The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair
Oncogene (2014)
-
Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers
Journal of Gastroenterology (2012)
-
Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice
Oncogene (2007)
-
MBD2 deficiency does not accelerate p53 mediated lymphomagenesis
Oncogene (2005)